Effect of Alendronate Sodium Combined with Alpha-Calciferol on Chronic Obstructive Pulmonary Disease with Osteoporosis

Abstract

We attempt to explore and study the effect of alendronate sodium combined with alpha-calciferol on chronic obstructive pulmonary disease patients with osteoporosis treatment and the changes of serum receptor activator for nuclear factor kappa B ligand and osteoprotegerin levels. We randomly selected 56 patients in the hospital from December 2021 to December 2022 as the study subjects. According to the time of admission, we divided them into two parts. 28 patients were given routine treatment as the control group and the other 28 patients were given alendronate sodium combined with alpha-calciferol as the observation group. Evaluate and compare both groups on the clinical efficacy rate and measure the serum receptor activator for nuclear factor kappa B ligand level and osteoprotegerin level after taking the fasting venous blood of the patients. The adverse reactions occurred during the treatment were counted and adverse reactions rate was calculated. The results showed that observation group had higher clinical control ratio and effective ratio than control group. In addition, observation group possessed higher clinical efficacy efficiency value of the patients than control group and the improvement was more obvious (p<0.05). In terms of serum level results, observation group had better data values of patients than control group. The serum receptor activator for nuclear factor kappa B ligand level, osteoprotegerin level, forced vital capacity 1 level and forced vital capacity 1/forced vital capacity values of patients in observation group were significantly improved than those in control group (p<0.05). In terms of adverse reaction evaluation, observation group during treatment had lower adverse reactions rate than control group (p<0.05). Alendronate sodium combined with alpha-calciferol can improve the clinical efficacy of chronic obstructive pulmonary disease and osteoporosis patients to a certain extent, and have a better effect on serum receptor activator for nuclear factor kappa B ligand, osteoprotegerin level and lung function.